Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the mouse model of MDS.
作者信息
Monlish Darlene A, Bhatt Sima T, Duncavage Eric J, Greenberg Zev J, Keller John L, Romine Molly P, Yang Wei, Aplan Peter D, Walter Matthew J, Schuettpelz Laura G
机构信息
Department of Pediatrics.
Department of Pathology, and.
出版信息
Blood. 2018 Mar 1;131(9):1032-1035. doi: 10.1182/blood-2017-08-801944. Epub 2018 Jan 22.
Abstract
摘要
相似文献
1
Loss of Toll-like receptor 2 results in accelerated leukemogenesis in the mouse model of MDS.
Blood. 2018 Mar 1;131(9):1032-1035. doi: 10.1182/blood-2017-08-801944. Epub 2018 Jan 22.
2
TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
Exp Hematol. 2020 Aug;88:42-55. doi: 10.1016/j.exphem.2020.07.001. Epub 2020 Jul 8.
3
Brief report: Loss of p15Ink4b accelerates development of myeloid neoplasms in Nup98-HoxD13 transgenic mice.
Stem Cells. 2014 May;32(5):1361-6. doi: 10.1002/stem.1635.
4
NUP98-HOX translocations lead to myelodysplastic syndrome in mice and men.
J Natl Cancer Inst Monogr. 2008(39):64-8. doi: 10.1093/jncimonographs/lgn014.
5
NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia.
Blood. 2005 Jul 1;106(1):287-95. doi: 10.1182/blood-2004-12-4794. Epub 2005 Mar 8.
6
Retroviral insertional mutagenesis identifies genes that collaborate with NUP98-HOXD13 during leukemic transformation.
Cancer Res. 2007 Jun 1;67(11):5148-55. doi: 10.1158/0008-5472.CAN-07-0075.
7
A NUP98-HOXD13 fusion gene impairs differentiation of B and T lymphocytes and leads to expansion of thymocytes with partial TCRB gene rearrangement.
J Immunol. 2009 Nov 15;183(10):6227-35. doi: 10.4049/jimmunol.0901121. Epub 2009 Oct 19.
8
Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Blood. 2016 Feb 4;127(5):616-25. doi: 10.1182/blood-2015-06-653113. Epub 2015 Dec 4.
9
Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1.
Blood. 2003 Jun 1;101(11):4529-38. doi: 10.1182/blood-2002-08-2484. Epub 2003 Jan 23.
10
NUP98 fusion in human leukemia: dysregulation of the nuclear pore and homeodomain proteins.
Int J Hematol. 2005 Jul;82(1):21-7. doi: 10.1532/IJH97.04160.
引用本文的文献
1
When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms.
Front Immunol. 2024 Feb 15;15:1339971. doi: 10.3389/fimmu.2024.1339971. eCollection 2024.
2
[Mechanisms by which the bone marrow microenvironment of myelodysplastic neoplasms contributes to disease progression].
Zhonghua Xue Ye Xue Za Zhi. 2023 Apr 14;44(4):350-352. doi: 10.3760/cma.j.issn.0253-2727.2023.04.018.
3
Restricting genomic actions of innate immune mediators on fetal hematopoietic progenitor cells.
iScience. 2023 Feb 28;26(4):106297. doi: 10.1016/j.isci.2023.106297. eCollection 2023 Apr 21.
4
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical Applications.
Diagnostics (Basel). 2022 Jul 7;12(7):1659. doi: 10.3390/diagnostics12071659.
5
IL-1β expression in bone marrow dendritic cells is induced by TLR2 agonists and regulates HSC function.
Blood. 2022 Oct 6;140(14):1607-1620. doi: 10.1182/blood.2022016084.
6
Context-dependent functions of pattern recognition receptors in cancer.
Nat Rev Cancer. 2022 Jul;22(7):397-413. doi: 10.1038/s41568-022-00462-5. Epub 2022 Mar 30.
7
Innate immune pathways and inflammation in hematopoietic aging, clonal hematopoiesis, and MDS.
J Exp Med. 2021 Jul 5;218(7). doi: 10.1084/jem.20201544. Epub 2021 Jun 15.
8
TLR2/6 signaling promotes the expansion of premalignant hematopoietic stem and progenitor cells in the NUP98-HOXD13 mouse model of MDS.
Exp Hematol. 2020 Aug;88:42-55. doi: 10.1016/j.exphem.2020.07.001. Epub 2020 Jul 8.
9
Contribution of Aberrant Toll Like Receptor Signaling to the Pathogenesis of Myelodysplastic Syndromes.
Front Immunol. 2020 Jun 17;11:1236. doi: 10.3389/fimmu.2020.01236. eCollection 2020.
10
Paralogous HOX13 Genes in Human Cancers.
Cancers (Basel). 2019 May 20;11(5):699. doi: 10.3390/cancers11050699.
本文引用的文献
1
The Role of Toll-Like Receptors in Hematopoietic Malignancies.
Front Immunol. 2016 Sep 28;7:390. doi: 10.3389/fimmu.2016.00390. eCollection 2016.
2
PUMA promotes apoptosis of hematopoietic progenitors driving leukemic progression in a mouse model of myelodysplasia.
Cell Death Differ. 2016 Jun;23(6):1049-59. doi: 10.1038/cdd.2015.159. Epub 2016 Jan 8.
3
Apoptosis in human myelodysplastic syndrome CD34+ cells is modulated by the upregulation of TLRs and histone H4 acetylation via a β-arrestin 1 dependent mechanism.
Exp Cell Res. 2016 Jan 1;340(1):22-31. doi: 10.1016/j.yexcr.2015.12.008. Epub 2015 Dec 17.
4
Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Blood. 2016 Feb 4;127(5):616-25. doi: 10.1182/blood-2015-06-653113. Epub 2015 Dec 4.
5
Loss of Tifab, a del(5q) MDS gene, alters hematopoiesis through derepression of Toll-like receptor-TRAF6 signaling.
J Exp Med. 2015 Oct 19;212(11):1967-85. doi: 10.1084/jem.20141898. Epub 2015 Oct 12.
6
Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Am J Hematol. 2015 Sep;90(9):831-41. doi: 10.1002/ajh.24102.
7
Deconstructing innate immune signaling in myelodysplastic syndromes.
Exp Hematol. 2015 Aug;43(8):587-598. doi: 10.1016/j.exphem.2015.05.016. Epub 2015 Jul 2.
8
Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.
Leukemia. 2015 Jul;29(7):1458-69. doi: 10.1038/leu.2015.69. Epub 2015 Mar 12.
9
Overexpression of the toll-like receptor (TLR) signaling adaptor MYD88, but lack of genetic mutation, in myelodysplastic syndromes.
PLoS One. 2013 Aug 15;8(8):e71120. doi: 10.1371/journal.pone.0071120. eCollection 2013.
10
Toll-like receptor alterations in myelodysplastic syndrome.
Leukemia. 2013 Sep;27(9):1832-40. doi: 10.1038/leu.2013.180. Epub 2013 Jun 14.
Zotero 插件